Business Context and Reporting Period
Company: Alnylam Pharmaceuticals, Inc.
Filing Type: Form 10-Q (Unaudited)
Period Ended: June 30, 2026
Business Overview: Alnylam is a global commercial-stage biopharmaceutical company developing RNAi therapeutics. As of June 30, 2026, the company has six marketed products (four commercialized directly: AMVUTTRA, ONPATTRO, GIVLAARI, OXLUMO; two by collaborators: Leqvio, Qfitlia) and over 25 clinical programs. The company achieved profitability in 2025 and continues to execute its "Alnylam 2030" strategy.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended June 30, 2026 |
Six Months Ended June 30, 2026 |
|---|---|---|
| Total Revenues | $1,290,948 | $2,458,123 |
| Net Product Revenues | $1,172,109 | $2,208,236 |
| Net Income (Loss) | $164,494 | $370,485 |
| Diluted EPS | $1.21 | $2.71 |
| Operating Cash Flow (6mo) | $397,228 | |
| Cash & Equivalents (Balance Sheet) | $1,708,318 | |
| Marketable Debt Securities | $1,599,829 | |
| Total Convertible Debt | $1,010,981 | |
| Accumulated Deficit | $(6,332,039) |
Material Changes vs. Prior Period
- Revenue Growth: Total revenues increased 67% year-over-year (Q2 2026 vs. Q2 2025) and 80% for the six-month period. Net product revenues grew 74% (Q2) and 94% (6 months), driven primarily by AMVUTTRA sales following its March 2025 FDA approval for ATTR-CM.
- Profitability: The company reported net income of $164.5 million for Q2 2026, compared to a net loss of $72.2 million in Q2 2025. Operating income improved from a loss of $16.2 million to income of $231.4 million.
- Product Performance:
- AMVUTTRA: Revenues surged 106% in Q2 and 137% in the six months ended June 30, 2026, reaching $1.01 billion (Q2) and $1.90 billion (6 months).
- ONPATTRO: Revenues declined 65% in Q2 and 62% in the six-month period due to patient migration to AMVUTTRA.
- GIVLAARI & OXLUMO: Both showed modest growth (11% and 11% respectively in Q2).
- Collaboration Revenue: Net revenues from collaborations decreased 23% in Q2 and 20% in the six-month period, primarily due to the wind-down of the Initial Research Term with Regeneron and lower recognized revenue under that agreement.
- Expenses: Cost of goods sold increased 110% in Q2, largely due to higher tiered royalties payable to Sanofi on AMVUTTRA sales. R&D expenses increased 28% in Q2, driven by Phase 3 trials for zilebesiran and nucresiran.
Guidance, Outlook, and Risks
- Strategic Outlook: Management expects to continue investing in R&D to advance the pipeline, including Phase 3 trials for nucresiran (ATTR-CM/PN) and zilebesiran (hypertension). The company aims to achieve ~30% non-GAAP operating margin by year-end 2030.
- Liquidity: Management believes cash, cash equivalents, marketable securities, and expected revenues will satisfy capital needs for at least the next 12 months. A $500 million revolving credit facility is available with no current borrowings.
- Key Risks:
- Regulatory & Legal: Ongoing patent litigation regarding ONPATTRO (University of Texas) and Leqvio (Cipla). A government investigation (subpoena) regarding price reporting for AMVUTTRA, ONPATTRO, OXLUMO, and GIVLAARI is ongoing.
- Commercial: Dependence on AMVUTTRA for a significant portion of revenue; potential impact of healthcare reform and pricing pressures (e.g., Inflation Reduction Act, executive orders on drug pricing).
- Collaboration: Reliance on third parties (Roche, Regeneron, Novartis, Sanofi) for development and commercialization of key assets like zilebesiran, cemdisiran, Leqvio, and Qfitlia.
- Debt: Significant liabilities related to the sale of future royalties (Blackstone) and convertible notes ($1.02 billion aggregate principal outstanding).
Investor Verification Checklist
- AMVUTTRA Royalty Structure: Verify the impact of tiered royalties payable to Sanofi on gross margins as AMVUTTRA sales exceed $1.5 billion annually.
- Blackstone Liability: Review the accretion of the $1.52 billion liability related to the sale of Leqvio royalties and the risk of the royalty interest increasing to 55% if the $1 billion threshold is not met by 2029.
- Regulatory Status: Monitor the status of the FDA/EMA review for cemdisiran (NDA accepted June 2026) and the outcome of the University of Texas patent litigation regarding ONPATTRO.
- Government Investigation: Track the resolution of the U.S. Attorney's Office subpoena regarding government price reporting.
- Convertible Notes: Assess the potential dilution or cash settlement requirements for the 2027 and 2028 convertible notes, particularly given the current stock price relative to conversion prices.